These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26742710)

  • 1. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
    Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
    J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.
    Bagni O; Filippi L; Pelle G; Cianni R; Schillaci O
    Cancer Biother Radiopharm; 2015 Dec; 30(10):421-6. PubMed ID: 26594900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
    Dunfee BL; Riaz A; Lewandowski RJ; Ibrahim S; Mulcahy MF; Ryu RK; Atassi B; Sato KT; Newman S; Omary RA; Benson A; Salem R
    J Vasc Interv Radiol; 2010 Jan; 21(1):90-5. PubMed ID: 19939705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
    Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
    Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
    Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
    Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.
    Gordon AC; Gradishar WJ; Kaklamani VG; Thuluvath AJ; Ryu RK; Sato KT; Gates VL; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2014 Oct; 25(10):1523-32, 1532.e1-2. PubMed ID: 25156827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.